Market closed

Citius Pharmaceuticals/CTXR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Citius Pharmaceuticals

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Ticker

CTXR
Trading on

Industry

Pharmaceuticals

Employees

22

CTXR Metrics

BasicAdvanced
$66M
Market cap
-
P/E ratio
-$0.24
EPS
1.68
Beta
-
Dividend rate
$66M
1.68
$1.07
$0.37
930K
6.745
4.314
0.098
0.371
-24.74%
-41.49%
0.77
3.92
-2.054
18.33%
-4.28%

What the Analysts think about CTXR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Citius Pharmaceuticals stock.

CTXR Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CTXR Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy CTXR

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Citius Pharmaceuticals stock?

Citius Pharmaceuticals (CTXR) has a market cap of $66M as of October 13, 2024.

What is the P/E ratio for Citius Pharmaceuticals stock?

The price to earnings (P/E) ratio for Citius Pharmaceuticals (CTXR) stock is 0 as of October 13, 2024.

Does Citius Pharmaceuticals stock pay dividends?

No, Citius Pharmaceuticals (CTXR) stock does not pay dividends to its shareholders as of October 13, 2024.

When is the next Citius Pharmaceuticals dividend payment date?

Citius Pharmaceuticals (CTXR) stock does not pay dividends to its shareholders.

What is the beta indicator for Citius Pharmaceuticals?

Citius Pharmaceuticals (CTXR) has a beta rating of 1.68. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.